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REDUCING AMYLOID BETA PEPTIDE PRODUCTION THROUGH 
REGULATION OF AMYLOID PRECURSOR PROTEIN DIMERIZATION 
ARMAN MEGUERIAN 
ABSTRACT 
Alzheimer’s disease is a progressive and irreversible neurodegenerative disorder 
characterized by the accumulation of neurotoxic Aβ peptides and subsequent onset of 
secondary neuropathological changes, including aggregation of hyperphosphorylated tau 
protein. Aβ peptides, produced through the successive actions of β- and γ-secretase in the 
amyloidogenic processing pathway of APP, aggregate into neurotoxic oligomeric Aβ and 
amyloid plaques. The reduction of Aβ peptide formation through the inhibition of β- and 
γ-secretase of the amyloidogenic pathway and the activation of α-secretase of the non-
amyloidogenic pathway has been a primary focus of many recent therapeutic research 
studies. Alternative strategies include increasing Aβ peptide clearance from the cerebral 
cortex through both active and passive immunization. Although some of these potential 
treatment options for Alzheimer’s disease have shown promise, they carry a great deal of 
risk with a variety of unintended side effects. Moreover, there are currently no disease-
modifying drugs available to treat Alzheimer’s disease, as most therapeutics are targeted 
to treat symptoms of the disease rather than the disease itself.  
Recent studies suggest a link between APP dimerization and Aβ production. 
Compound Y, which inhibited APP dimerization, was discovered by Pauline So and her 
colleagues in the Abraham lab at Boston University and was shown to reduce Aβ 
production by lowering sAPPβ levels, suggesting that the inhibition of APP dimerization 
  vii 
affects the β-secretase cleavage of APP. A kinase profiling assay revealed that compound 
Y10, an analog of compound Y, exhibited its action through the inhibition of receptor 
tyrosine kinase cKit. Interestingly, inhibition of cKit enhanced APP phosphorylation, 
suggesting that cKit indirectly affects APP. Known cKit interactors with potential to 
affect downstream APP phosphorylation were studied, leading to the discovery of Shp2, a 
tyrosine phosphatase directly linked to cKit signaling. After demonstrating that known 
Shp2 inhibitors increase APP phosphorylation and lower Aβ production, it was 
hypothesized that both cKit and Shp2 are involved in APP processing. 
The objective of the current study is to explore the potential for Shp2 as a novel 
therapeutic target in Alzheimer’s disease. Potential Shp2-inhibiting compounds, 
synthesized in collaboration with Dr. John Porco and his colleagues at the Center for 
Molecular Discovery at Boston University, were screened for their ability to inhibit Shp2 
using 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as a substrate. Five 
compounds were shown to significantly inhibit Shp2, and these compounds were 
subsequently tested in a dose-dependent manner to determine their potency. All five 
compounds compared favorably with the potency of a known Shp2 inhibitor. As a result, 
these five compounds have become lead candidates in the next stage of evaluation. 
 With a growing aging population and an ever-increasing economic burden placed 
on global healthcare systems, there is a pressing need to develop a disease-modifying 
treatment for Alzheimer’s disease. This study contributes to the scientific knowledge 
behind Alzheimer’s disease and provides the necessary tools for the discovery of 
potential therapeutics.  
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INTRODUCTION 
 
 In 1906, Alois Alzheimer gave a groundbreaking lecture at the 37
th
 Conference of 
South-West German Psychiatrists in Tübingen, Germany. He described to his colleagues 
the clinical case of patient Auguste Deter, a 51-year-old woman from Frankfurt who had 
presented with a myriad of symptoms including progressive cognitive impairment, 
delusions, and psychological incompetence. Post-mortem examination revealed “miliary 
foci…which represented the sites of deposition of a peculiar substance in the cerebral 
cortex” (Alzheimer, 1911). The “peculiar substance” Alzheimer observed is now known 
to be amyloid β (Aβ) peptide, which was first isolated by George Glenner in 1984 
(Glenner & Wong, 1984). With the knowledge of the amino acid sequence of Aβ 
elucidated from Glenner’s seminal work, the amyloid β precursor protein (APP) was 
cloned in 1987 (Kang et al., 1987). The cloning of APP marked the beginning of a new 
age for Alzheimer’s research. 
Alzheimer’s disease, as it is presently understood, is a progressive and irreversible 
neurodegenerative disorder characterized by Aβ deposition in the brain with subsequent 
formation of neuritic plaques and neurofibrillary tangles leading to dementia (Awasthi, 
Singh, Pandey, & Dwivedi, 2016). A 2012 report, jointly developed by the World Health 
Organization (WHO) and Alzheimer’s Disease International (ADI), estimates that 35.6 
million people worldwide are currently living with dementia (WHO, 2012), with 
Alzheimer’s disease accounting for 55%-70% of adult-onset dementia in the 
industrialized world (Lim et al., 1999). Moreover, this figure is expected to nearly double 
to 65.7 million by 2030 and more than triple to 115.4 million by 2050 (WHO, 2012). One 
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major reason for this exponential trend is the rapid growth of the aging population 
(Figure 1). Although only 2%-10% of all cases of dementia have been reported to start 
before the age of 65, the prevalence doubles with every 5-year increment in age after 65 
(Corrada, Brookmeyer, Paganini-Hill, Berlau, & Kawas, 2010).  
Figure 1: Estimates of worldwide population over the age of 60. By 2050, it is 
estimated that the world population over the age of 60 will reach 2 billion. Figure taken 
from World Health Organization and Alzheimer’s Disease International, 2012. 
 
The rapidly growing aging population, in conjunction with the increased 
prevalence of Alzheimer’s disease, is placing a massive economic burden on global 
healthcare systems. In 2015 alone, total payments for all individuals with Alzheimer’s 
disease and other dementias in the United States were estimated at $226 billion, with out-
of-pocket spending accounting for 19% ($44 billion) of the cost (“Alzheimer’s 
Association,” 2015). Total yearly healthcare costs for people with Alzheimer’s disease 
and other dementias were $47,752 per person, more than three times as much as 
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payments for people without dementia ($15,115 per person) in the same age bracket. 
Total healthcare costs for people with Alzheimer’s disease and other dementias are 
expected to increase from $226 billion in 2015 to $1.1 trillion in 2050, which includes a 
five-fold increase in government spending and a near five-fold increase in out-of-pocket 
spending (“Alzheimer’s Association,” 2015). 
Although there are treatments currently available to alleviate a variety of 
symptoms associated with Alzheimer’s disease, a disease-modifying treatment has not 
yet been identified. With the rapid growth of the aging population and increased 
economic burden being placed on global healthcare systems, there is a pressing need to 
improve the understanding of Alzheimer’s disease pathogenesis through research to 
enable the development of disease-modifying treatments. 
 
Genetic Risk Factors 
Though the etiology of Alzheimer’s disease proved to be elusive for most of the 
20
th
 century, a significant discovery greatly altered the understanding of this disease. In 
1981, Leonard Heston studied relatives of 125 subjects who had been confirmed to have 
Alzheimer’s disease through post-mortem evaluation. His study showed that the relatives 
of affected individuals exhibited an excess of dementia consistent with genetic 
transmission (Heston, Mastri, Anderson, & White, 1981). In the same study, Heston 
noted that relatives of patients with Alzheimer’s disease derived from families with a 
significantly greater incidence of Down syndrome (trisomy 21), indicating a possible link 
between chromosome 21 and Alzheimer’s disease. Through the elucidation of the amino 
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acid sequence of Aβ protein (Glenner & Wong, 1984) and the isolation of the gene 
encoding APP (Kang et al., 1987), the APP gene was mapped to chromosome 21 (Price, 
Tanzi, Borchelt, & Sisodia, 1998), confirming Heston’s suspicions. The sequencing of 
exons 16 and 17 of APP, which encode the Aβ domain, revealed the first pathogenic 
mutation in APP (Levy et al., 1990). This mutation was found to cause hereditary 
cerebral hemorrhage with amyloidosis linked to chromosome 21 (St George-Hyslop et 
al., 1990). Though additional mutations in APP were subsequently identified, it became 
apparent that these mutations represented a small fraction of all early-onset familial 
Alzheimer’s disease cases.  
In 1995, Levy-Lahad and colleagues identified presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) as novel early-onset familial Alzheimer’s disease genes on 
chromosomes 14 and 1, respectively (Levy-Lahad et al., 1995). PSEN1 and PSEN2 
(Figure 2) are transmembrane proteins containing large hydrophilic, cytoplasmic loops 
which undergo proteolytic cleavage leading to amino and carboxy terminal fragments 
(Thinakaran et al., 1997). The presenilins are required to produce Aβ peptides from APP 
(De Strooper et al., 1998). To date, 140 rare autosomal-dominant mutations have been 
discovered in PSEN1, and 10 have been discovered in PSEN2 (Cruts, Theuns, & Van 
Broeckhoven, 2012). 
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Figure 2: Schematic representation of presenilin 1 and presenilin 2. PSEN1 and 
PSEN2 help form a functional complex that plays an important role in generating Aβ 
peptide. Early-onset familial Alzheimer’s disease is linked to mutations in presenilin, 
which enhance γ-secretase activity and subsequently increase Aβ production. Figure 
taken from Mattson, 2003.   
 
In the same year that the first early-onset familial Alzheimer’s disease mutation 
was found in APP, a significant genetic linkage was reported between chromosome 19 
and the late-onset form of Alzheimer’s disease (Pericak-Vance et al., 1991). A common 
polymorphism, ϵ4, was later identified in the gene encoding apolipoprotein E (ApoE), 
found in the chromosomal region linked to increased risk of late-onset Alzheimer’s 
disease (Saunders et al., 1993). Although carrying one or two copies of the ϵ4 allele of 
ApoE is neither sufficient nor necessary to cause Alzheimer’s disease, its presence has 
been shown to reduce the age of onset for the disease (Blacker et al., 1997). The table 
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below summarizes the four major genes associated with Alzheimer’s disease, including 
their location on the human chromosome, and form of inheritance. 
 
Table 1: Overview of Alzheimer’s disease genes, their chromosomal location, and 
form of inheritance. Table taken from Bekris, Yu, Bird, & Tsuang, 2010. 
 
 
 
 
 
 
 
 
 
Amyloid β Precursor Protein and the Amyloid Cascade Hypothesis 
Amyloid β precursor protein (APP), a type I transmembrane protein, has a 
carboxyl-terminus within the cytosol and amino-terminus within the lumen (Kang et al., 
1987). The proteolytic processing of APP at various subcellular sites by α-, β-, and γ-
secretases plays a major role in the development of Alzheimer’s disease (Weidemann et 
al., 1989). The two major pathways in which APP is processed are termed 
amyloidogenic, in which Aβ is generated, and non-amyloidogenic, in which Aβ 
generation is prevented (Haass, 2004). In the amyloidogenic pathway, the production of 
Aβ from APP is achieved through the successive actions of β- and γ-secretase which 
release Aβ into extracellular fluids such as plasma or cerebrospinal fluid (Seubert et al., 
1992). Full-length APP is first cleaved by β-secretase, resulting in the release of a large 
 7 
soluble ectodomain sAPPβ and the retention of membrane-bound carboxyl-terminal 
fragment (APP-CTFβ). Subsequent cleavage of APP-CTFβ by γ-secretase releases the 
APP intracellular domain (AICD) and generates extracellular Aβ peptides 38-43 amino 
acids in length. In the non-amyloidogenic pathway, APP is initially cleaved by α-
secretase, which generates a truncated CTF transmembrane domain (APP-CTFα) lacking 
the amino-terminal of the Aβ domain (Sisodia, Koo, Beyreuther, Unterbeck, & Price, 
1990). The subsequent cleavage of APP-CTFα by γ-secretase generates a biologically 
irrelevant truncated Aβ peptide, p3, in addition to AICD. The amyloidogenic and non-
amyloidogenic processing pathways of APP are competitive in nature. Enhancing α-
secretase activity in animal models or cultured cells has been shown to significantly 
lower Aβ production and the subsequent formation of amyloid plaques (Nitsch, Slack, 
Wurtman, & Growdon, 1992; Postina et al., 2004). 
 
Figure 3: Overview of APP processing. APP is processed through the amyloidogenic 
pathway, in which Aβ peptides are produced, or the non-amyloidogenic pathway, in 
which Aβ production is prevented. Figure taken from Zhang and Saunders, 2009.  
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The Aβ peptides produced through the amyloidogenic pathway are 39-43 amino 
acids in length, but the predominant forms are Aβ40 and Aβ42 (Abraham, 2011). The 
normal physiological ratio between Aβ42 and Aβ40 peptides is 1:10, with the ratio being 
increased in familial Alzheimer’s disease (Abraham, 2011). Both types of peptide 
monomers can form protofibrils, fibrils, and plaques depending on the extent of 
oligomerization (Abraham, 2011). Aβ peptides linked together through hydrogen bonds 
form protofibrils, which can themselves aggregate to form fibrils. Further aggregation of 
fibrils generates amyloid plaques which are highly neurotoxic (Masters et al., 1985; 
Sandberg et al., 2010). Compared with Aβ40, Aβ42 contains two additional hydrophobic 
amino acids at its carboxyl-terminus, making it more prone to aggregate. Oligomeric 
forms of Aβ1-42 have been shown to be the most toxic forms of the peptide (Haass, 
2010; Selkoe, 2008). 
According to the prevalent theory of Alzheimer’s disease pathology, termed the 
amyloid cascade hypothesis, mutations in APP, PSEN1, and PSEN2 genes affect APP 
processing and lead to the overproduction of Aβ peptides and subsequent formation of 
amyloid plaques in the brain. Extracellular and intracellular depositions of Aβ peptides 
instigate a cascade of events leading to secondary neuropathological changes such as 
accumulation of hyperphosphorylated tau, formation of neurofibrillary tangles (NFTs), 
synaptic degeneration, neuronal cell death, and dementia. Though the intracellular 
accumulation of hyperphosphorylated tau forming NFTs and the extracellular deposition 
of Aβ forming neurotoxic amyloid plaques are both considered major pathological 
hallmarks of Alzheimer’s disease, evidence suggests that the deposition of tau is a 
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consequence of Aβ plaque accumulation (Hardy, Duff, Hardy, Perez-Tur, & Hutton, 
1998). The amyloid cascade hypothesis has provided the impetus to explore a wide 
variety of therapeutic interventions that target Aβ production, aggregation, or clearance 
(Figure 4).  
 
Figure 4: The amyloid cascade hypothesis. The amyloid cascade hypothesis posits that 
mutations in APP, presenilin 1, and presenilin 2 cause abhorrent Aβ production, leading 
to a series of secondary neuropathological changes. Figure taken from Awasthi, Singh, 
Pandey, & Dwivedi, 2016.  
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Current Treatment Options 
Currently, two symptomatic treatment methods for Alzheimer’s disease have been 
approved by the Food and Drug Administration: acetylcholinesterase inhibitors and N-
methyl-D-aspartate (NMDA) receptor antagonists (Awasthi, Singh, Pandey, & Dwivedi, 
2016). Acetylcholinesterase inhibitors, including rivastigmine, donepezil, and 
galantamine, prevent the breakdown of acetylcholine, allowing for increased cholinergic 
transmission and improved cognition in patients with Alzheimer’s disease (Mangialasche, 
Solomon, Winblad, Mecocci, & Kivipelto, 2010). These inhibitors have modest effects 
on cognition and have greater efficacy in mild cases of Alzheimer’s disease (Herrmann, 
Chau, Kircanski, & Lanctôt, 2011). NMDA receptor antagonists, such as memantine, 
prevent excitotoxicity, which is the cause of memory damage in Alzheimer’s disease 
(Makino & Porsteinsson, 2011). Although both these treatments can improve functioning 
and cognition, they do not interrupt the progression of Alzheimer’s disease. Therefore, 
there is a need for drugs that target the formation of Aβ proteins which aggregate to form 
toxic oligomers and plaques and which cause neuronal dysfunction (Herrmann et al., 
2011). Current strategies focus on decreasing Aβ production and on clearance of Aβ 
(Awasthi et al., 2016).  
Decreasing Aβ Production  
Therapeutic strategies have focused on reducing Aβ by both inhibiting β- and γ-
secretases, the two enzymes involved in producing Aβ from APP, and increasing the 
activity of α-secretase, the enzyme that reduces Aβ production (Awasthi et al., 2016). 
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β-Secretase Inhibitors  
 
BACE1, an aspartyl protease, cleaves the β-site of APP, allowing for cleavage by  
γ-secretase to produce Aβ (Awasthi et al., 2016). Inhibiting this enzyme in mouse models 
has been found to prevent the formation of Aβ and cholinergic dysfunction (Ohno et al., 
2004). Although β-secretase inhibitors appear promising in the treatment of Alzheimer’s 
disease, inhibition of BACE1 could potentially cause hypomyelination, leading to 
behavioral impairments, memory deficits, and seizures (Kobayashi et al., 2008).  
γ-Secretase Inhibitors  
 
γ-Secretase, a transmembrane protease that is responsible for the final cleavage of 
APP to produce Aβ, represents another potential therapeutic target (Awasthi et al., 2016). 
Because γ-secretase affects many substrates, it has a propensity to cause side effects 
(Bergmans & De Strooper, 2010). For example, γ-secretase acts on the substrate Notch 1, 
causing the release of the Notch intracellular domain (NICD) into the nucleus to regulate 
transcription and cell differentiation. Thus, γ-secretase inhibitors, through inhibition of 
Notch, have been found to cause gastrointestinal bleeding, skin irritations, and hair loss 
(Bergmans & De Strooper, 2010).  
α-Secretase Activators  
 
Increasing the activity of α-secretase, which cleaves APP within the Aβ region, 
prevents the formation of Aβ and produces soluble APPα, which can be neuroprotective. 
However, the actions of α-secretase may be due to multiple proteases and thus difficult to 
target pharmacologically (Nunan & Small, 2000). Furthermore, atorvastatin, a drug that 
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activates α-secretase, has been shown to have many side effects, including fever, nausea, 
muscle aches, weight gain, jaundice, and increased drinking and urination (Awasthi et al., 
2016). 
Aβ Clearance  
Removing aggregated Aβ from the cerebral cortex can help to mitigate the  
detrimental effects of Alzheimer’s disease (Awasthi et al., 2016). Active immunization, 
which involves the inoculation of full Aβ peptides, and passive immunization, achieved 
through the administration of premade Aβ antibodies, are two suggested strategies to 
facilitate Aβ clearance (Herrmann et al., 2011). According to Schenk et al., (1999), active 
immunization of Aβ42 in mouse models prevented the accumulation of Aβ. However, in 
human patients with Alzheimer’s disease, active immunization has been found to cause 
aseptic meningoencephalitis and cerebral microhemorrhage because of the activation of 
cytotoxic T-cells (Herrmann et al., 2011). Passive immunization facilitates clearance of 
amyloid plaques and also reduces hyperphosphorylation of tau. Furthermore, it has been 
shown to be a safer and more effective alternative in elderly patients when compared with 
active immunization (Awasthi et al., 2016; McElhaney & Effros, 2009). Nevertheless, 
side effects can occur with the administration of antibodies, including fever, nausea, 
transient confusion, and microhemorrhage (Bohrmann et al., 2012; Relkin et al., 2009).  
 Most current treatment options for Alzheimer’s disease are aimed at alleviating 
symptoms rather than modifying the disease itself. Those treatments that attempt to 
modify the disease carry a great deal of risk, with a myriad of complications arising from 
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unwanted side effects. There is a growing need for a novel therapeutic strategy which 
addresses the root cause of the disease while limiting potential risk. 
 
Targeting APP Dimerization as a Novel Therapeutic 
 The structure of the APP single-pass transmembrane glycoprotein resembles a 
cell-surface receptor which has the potential to bind to ligands and participate in protein-
protein interactions (Kang et al., 1987). APP has the ability to form homodimers 
(Scheuermann et al., 2001) in addition to heterodimers with Notch for cellular signaling 
(Chen, Oh, Hinman, & Abraham, 2006). APP can also form heterodimers with its 
homologs, the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2), for cellular 
adhesion and cell-to-cell communication (Kaden et al., 2009; Soba et al., 2005). 
Although the precise function and significance of APP dimerization are unclear, the 
mechanism has been linked to many biological activities including gene transcription and 
cellular metabolism (Cao & Südhof, 2004; von Rotz et al., 2004), platelet aggregation 
(Bush et al., 1990), and metal homeostasis (Bellingham et al., 2004; Duce et al., 2010). 
APP dimerization has also been linked to several neuronal processes such as cellular 
growth (Klar, Baldassare, & Jessell, 1992), differentiation (Kwak et al., 2006), migration 
(Young-Pearse et al., 2007), arborization (Qiu, Ferreira, Miller, Koo, & Selkoe, 1995), 
axonal transport (Kamal, Almenar-Queralt, LeBlanc, Roberts, & Goldstein, 2001), 
memory formation (Meziane et al., 1998), and neuroprotection (Gralle, Botelho, & 
Wouters, 2009). 
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 Recent studies suggest a possible link between APP dimerization and Aβ 
production (Figure 5). Scheuermann and colleagues showed that replacing a lysine 
residue with a cysteine residue at the juxtamembrane region of APP led to constitutive 
dimerization of APP and a concomitant increase in Aβ levels (Scheuermann et al., 2001). 
Furthermore, mutations which disrupt the GxxxG transmembrane dimerization motif of 
APP have been shown to reduce the levels of toxic Aβ42 (Munter et al., 2007).  
 
Figure 5: Schematic representation of APP dimerization. APP dimerization has been 
shown to increase Aβ production. Figure amended from Scheuermann et al., 2001.  
 
 
To assess the association between APP dimerization and Aβ peptide generation, 
Pauline So and her colleagues at the Abraham Laboratory at Boston University developed 
a method to identify small-molecule inhibitors of APP dimerization and study their 
effects on Aβ production. Firefly luciferase enzyme fragment complementation (FLuc 
EFC) was used to conduct a high-throughput screening (HTS) in an effort to detect APP-
APP interactions. To do so, two inactive deletion mutants of the FLuc enzyme, N-
terminal (FLucN) fragment and C-terminal (FLucC) fragment, were separately fused to 
APP. The FLuc fragments remain inactive if APP remains in its monomeric form. 
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However, upon dimerization, the two previously inactive FLuc fragments reconstitute to 
form a fully functional enzyme (Figure 6). The APP-APP interactions were quantified by 
adding luciferase substrate and measuring chemiluminescence (So et al., 2012). 
Figure 6: Schematic diagram of the APP FLuc EFC system. Deletion mutants FLucN 
and FLucC were separately fused to APP, combining to form a fully functional enzyme 
upon APP dimerization. The construct of APP fused to full-length firefly luciferase (APP 
FLuc FL) was used as a positive control. Figure taken from So et al., 2012.  
 
Of the 77,440 small molecules screened by So et al. (2102) from the compound 
library, 113 compounds lowered luciferase signal by a minimum of 50%. The 113 
compounds were then tested for dose-response effects and cell toxicity. Of the 113 
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remaining compounds, 14 were non-cytotoxic and showed dose-response effects (Figure 
7). Two of the 14 compounds, named compound X and compound Y, were selected for 
further evaluation based on their relative potency and lack of cell toxicity (So et al., 
2012). 
 
Figure 7: Twelve-point dose-response and toxicity curves for compounds X and Y. 
(A) Increasing concentration of either compound X or compound Y increased inhibition 
of the assay signal, correlating to an increase of inhibition of APP dimerization. (B) 
Toxicity curves showed compounds X and Y to be non-toxic to cells. Figure taken from 
So et al., 2012. 
 
Compounds X and Y were studied for their effects on Aβ production by treating 
cells stably transfected with untagged wild-type APP. Results showed that cells treated 
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with compound X did not display a significant difference in Aβ production, whereas cells 
treated with compound Y showed a significant reduction in both Aβ40 and Aβ42 (Figure 
8). Neither compound X nor compound Y affected the Aβ42:Aβ40 ratio for treated cells 
when compared with the dimethyl sulfoxide (DMSO) control (So et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Effects of compounds X and Y on Aβ40 and Aβ42 production. (A) 
Compound X did not significantly affect Aβ40 levels compared with the DMSO control, 
though it did show a slight decrease. Compound Y was shown to significantly reduce 
Aβ40 (p < 0.05). (B) Compound X did not significantly affect Aβ42 levels compared 
with the DMSO control, though it did show a slight decrease. Compound Y was shown to 
significantly reduce Aβ42 (p < 0.05). (C) Neither compound X nor compound Y had a 
significant effect on the Aβ42:Aβ40 ratio compared with the DMSO control. Figure taken 
from So et al., 2012.  
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The effects of compounds X and Y on APP protein expression and processing 
were examined by analyzing treated cells for expression of total protein, sAPPα 
(indicating level of α-secretase processing), sAPPβ (indicating level of β-secretase 
processing), and γ-CTFs C99 and C83 (indicating level of γ-secretase processing 
following β- or α-secretase, respectively). Results of the experiment indicated that 
compounds X and Y have no significant effect on the expression of APP and most of its 
processed products when compared with the DMSO control (Figure 9). However, there 
was a significant reduction in sAPPβ release in cells treated with compound Y. With no 
change evident in C99 levels, this suggests that compound Y may lower the production of 
Aβ40 and Aβ42 by altering β-secretase activity (So et al., 2012).  
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Figure 9: Effects of compounds X and Y on APP processing. (A) Western blots 
illustrate the effects of compounds X and Y on APP protein expression and APP 
processing products sAPPα, sAPPβ, and γ-CTFs (C99 and C83). (B) Densitometric plots 
quantifying the effects of compounds X and Y on APP processing indicate that 
compound X does not significantly affect APP expression and its processed products 
compared with the DMSO control. Compound Y, however, was shown to significantly 
reduce sAPPβ (p < 0.05). Figure taken from So et al., 2012. 
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A series of structural analogs to compound Y were tested for improved efficacy in 
Aβ reduction. Structural analog Y10 was identified as a compound which inhibited APP 
dimerization in a dose-dependent manner. Y10 was profiled for inhibitory activity against 
a panel of 69 kinases. The results of the screening showed that the sole kinase inhibited 
by Y10 was the receptor tyrosine kinase cKit (Figure 10). The cKit receptor is a type III 
receptor tyrosine kinase characterized by five immunoglobulin-like domains and an 
intracellular split tyrosine kinase domain (Liang et al., 2013). It has been found to have 
an important role in hematopoietic cell proliferation, differentiation, and regulation of 
growth and development (Chen & Xiong, 2002).  
 
Figure 10: Structure of receptor tyrosine kinase cKit. The cKit receptor tyrosine 
kinase is characterized by five immunoglobulin-like domains and an intracellular split 
tyrosine kinase domain. Figure taken from Lennartsson & Rönnstrand, 2012.  
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The precise mechanism of action of Y10 was elucidated by examining its effect 
on APP phosphorylation using immunoprecipitation (IP)-Western blotting (Chen et al., 
unpublished). Y10 was shown to inhibit cKit phosphorylation and increase APP 
phosphorylation (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Effects of compound Y10 on APP phosphorylation through cKit. (A) IP-
Western blot analysis shows the effects of compound Y10 at 1 μM on APP 
phosphorylation of empty vector or cKit-transfected APP stable cells. Y10 was found to 
enhance APP phosphorylation on a tyrosine residue. Anti-p-Y = antibody to 
phosphotyrosine; 6E10 = monoclonal antibody that recognizes APP and Aβ. (B) IP-
Western blot analysis shows the effects of compound Y10 on cKit. In this experiment, 
cKit contains a V5 tag that is recognized by anti-V5 antibodies. Compound Y10 was 
shown to inhibit cKit autophosphorylation. Figure taken from Chen et al., unpublished.  
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Of the eight potential phosphorylation sites within the APP cytoplasmic domain, 
seven have been shown to be phosphorylated in brains with Alzheimer’s disease: Y653, 
S655, T668, S675, Y682, T686, and Y687 (Lee et al., 2003). The YENPTY motif of APP 
plays a pivotal role in APP processing and Aβ production. Phosphorylation of the 
YENPTY motif on T668, Y682, and Y687 is essential for regulating APP endocytosis, 
APP processing, and Aβ production (Lee et al., 2003; Matrone et al., 2012; Suzuki & 
Nakaya, 2008). Phosphorylation of Y682 and T668 has been shown to increase Aβ 
production (Lee et al., 2003), whereas phosphorylation of Y687 results in a reduction of 
Aβ production, a likely byproduct of altered cell surface localization (Rebelo et al., 
2007). 
 The Y10 compound was previously shown to enhance APP phosphorylation 
through its action on a tyrosine residue (refer to Figure 11). The three tyrosine residues in 
the cytoplasmic domain of APP (Y653, Y682, and Y687) were investigated to identify 
the specific site of phosphorylation (Figure 12). Y10 was confirmed to increase APP 
phosphorylation through its action on tyrosine residue Y687 by site-directed mutagenesis. 
Figure 12: Schematic diagram of the YENPTY motif of APP. Tyrosine residues 
Y653, Y682, and Y687 (indicated by arrows) were investigated to identify the specific 
site of action of compound Y10. Y687 was confirmed to be the site of action for 
compound Y10. Figure taken from Chen et al., unpublished.  
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 After the identification of cKit as a target for compound Y10, known cKit 
interactors with potential to affect downstream APP phosphorylation were studied 
(Figure 13). Among cKit-interacting proteins are Src homology protein tyrosine 
phosphatase-2 (Shp2) and scaffolding protein Gab2, which both bind to cKit through 
growth factor receptor-binding protein-2 (Grb2) and Src homology adaptor protein (Shc). 
Following activation of cKit by stem cell factor (SCF), Gab2 becomes tyrosine-
phosphorylated through Grb2-dependent recruitment and Src-mediated phosphorylation 
(Sun, Pedersen, & Rönnstrand, 2008; Yu et al., 2006). This phosphorylation event leads 
to Shp2 recruitment, a critical step for SCF-induced activation of the mitogen-activated 
protein kinase (MAPK) pathway (Yu et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Current model for potential interactions between APP, cKit, Shp2, and 
Gab2. Gab2, a scaffolding protein, and Shp2 bind to cKit through Grb2 and Shc. 
Phosphorylation of Gab2 leads to Shp2 recruitment and subsequent SCF-induced 
activation of the MAPK pathway. Compound Y10 has been shown to increase APP 
phosphorylation through cKit. Figure taken from Chen et al., unpublished.  
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 The role of Shp2 in APP phosphorylation was confirmed by an assay with three 
known Shp2 inhibitors (II-B08, PHPS1, and NSC-87877) (Chen et al., unpublished). The 
results indicated an increase in APP phosphorylation and a reduction in Aβ production in 
HEK293 cells and primary mouse hippocampal neurons (Figure 14).  
Figure 14: Shp2 inhibitors NSC-87877, II-B08, and PHPS1 enhance APP 
phosphorylation and reduce Aβ40. (A) IP-Western blot analysis of the effects of Shp2 
inhibitors NSC-87877, II-B08, and PHPS1 at 1 μM in APP stable cells shows an 
enhancement of APP phosphorylation. (B) Enzyme-linked immunosorbent assay 
(ELISA) of Shp2 inhibitors NSC-87877, II-B08, and PHPS1 at 1 μM indicates a 
significant reduction of Aβ40 levels. (C) IP-Western blot analysis of Y10 and Shp2 
inhibitors NSC-87877, II-B08, and PHPS1 shows an increase in APP phosphorylation in 
primary mouse hippocampal neurons. Figure taken from Chen et al., unpublished. 
 
The knowledge that Shp2 inhibitors increase APP phosphorylation and reduce Aβ 
production (similar to cKit inhibitor Y10) suggests the hypothesis that cKit-mediated 
recruitment of Shp2 is crucial for APP dephosphorylation. Based on this hypothesis, the 
current study aims to reduce levels of neurotoxic Aβ peptide in the brain by identifying 
and optimizing small-molecule modulators of APP phosphorylation through Shp2 
inhibition. Shp2 represents a completely novel drug target for Alzheimer’s disease.   
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SPECIFIC AIMS 
 
The objective of the present study is to determine the role of Shp2 inhibition in APP 
processing and to explore the potential for Shp2 as a novel therapeutic target in 
Alzheimer’s disease. Specifically, the aims are to collaborate with the Center for 
Molecular Discovery at Boston University (Boston, MA) to: 
1. Use a structure-based approach to develop and optimize novel central nervous 
system (CNS)-penetrant Shp2 inhibitors based on known Shp2-inhibitory 
chemotypes, in silico docking, and fragment assembly. 
2. Assess the viability of potential Shp2 inhibitors using a high-throughput screening 
enzymatic assay. 
3. Determine the potency of test compounds which passed initial screening by 
retesting the samples in a dose-dependent manner. 
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METHODS 
 
GST-Shp2 Purification 
Glutathione S-transferase (GST)-Shp2 fusion proteins were expressed in 
Escherichia coli DH5α cells induced overnight with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). The bacterial pellets were resuspended in phosphate-
buffered saline (PBS) containing protease inhibitors. The samples were placed on ice and 
sonicated for 30 seconds, 4-6 times, using a Fisher Scientific Series 60 Sonic 
Dismembrator (Pittsburgh, PA). A quantity of 50% Tween 20 (20 μL) was added to each 
sample, and the tubes were incubated end-over-end for 30 minutes. The samples were 
centrifuged at 12,000 g for 10 minutes. While centrifuging the sample, glutathione beads 
were prepared for use by washing with PBS 3 times (200 μL of glutathione beads for 1 L 
of culture). The centrifuged lysate was transferred to the tube containing pre-washed 
glutathione beads and incubated end-over-end for 2-3 hours at 4 °C. The solution was 
washed with PBS 3 times prior to elution. The elution buffer used to extract the GST-
Shp2 was prepared with 3.6 mL H2O, 1 mL 100 mM glutathione, 0.25 mL 1 M 
Tris(hydroxymethyl)aminomethane (Tris) at pH 8.0, 0.15 mL 5 M NaCl, and 5 μL 2-
mercaptoethanol. The solution was eluted three times over a 2-hour period and was 
centrifuged at 1500 rpm for 3 minutes at 4 °C after each elution step. The solution was 
then placed in a Millipore Microcon Ultracel YM-30 Centrifugal Filter Device (Bedford, 
MA), which allows the passage of biomolecules with a nominal molecular weight limit 
(NMWL) of 30 kDa or below. The filter device was filled with Shp2 buffer containing 
12.5 mM Tris at pH 7.2, 25 mM NaCl, 1 mM dithiothreitol (DTT), and 0.1% 2-
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mercaptoethanol. The sample was centrifuged at 4000 rpm for 10 minutes at 4 °C. The 
filter device containing the sample was filled with Shp2 buffer and centrifuged an 
additional 2 times at the same conditions. Upon completion, the concentration of GST-
Shp2 was measured using the Thermo Scientific NanoDrop 2000 (Waltham, MA) and 
accompanying software. Shp2 buffer was used as a blank, and Thermo Scientific Bovine 
Serum Albumin Standard (2 mg/mL) was used as a control. The purified GST-Shp2 was 
aliquoted into a volume corresponding to use for a single plate of test compounds and 
stored in 20% glycerol at -80 °C. 
 
Test Compounds 
In collaboration with Dr. John Porco and his colleagues at the Center for 
Molecular Discovery at Boston University, a massive compound library of prospective 
Shp2 inhibitors was developed. Potential Shp2 inhibitors were constructed to incorporate 
cation-binding features present in known Shp2 inhibitors while also retaining 
physiochemical properties necessary for future applications in CNS drug discovery. 
Potential Shp2 inhibitors were sent to the laboratory as dry aliquots (0.2 μmol) on 96-
well plates. The compounds were diluted to 0.4 mM stock solutions using DMSO. A final 
concentration of 10 μM was used for screening purposes. 
 
PTP Activity Assay 
Protein tyrosine phosphatase (PTP) activity was measured using the fluorogenic 
substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP; Invitrogen, Carlsbad, 
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CA). Unless otherwise specified, each reaction contained 312.5 ng GST-Shp2, 50 mM 
Tris at pH 7.2, 50 mM NaCl, 0.05% Tween 20, 1 mM DTT, 20 μM DiFMUP, and 2.5 μL 
of the test compound in a total reaction volume of 100 μL (1 well) in black 96-well 
plates. Quantities (2.5 μL) of DMSO and the known Shp2 inhibitor, 
phenylhydrazonopyrazolone sulfonate 1 (PHPS1), were used in the same assay in place 
of the test compound in the total reaction volume to obtain positive and negative controls, 
respectively. The reaction was initiated by addition of DiFMUP, followed by incubation 
for 10 minutes at room temperature. The DiFMUP fluorescence signal was measured at 
an excitation of 365 nm and an emission of 410-460 nm with a Promega GloMax Multi 
Detection System (Madison, WI). 
 
Dose-Response Tests 
 Test compounds which showed promising results in terms of Shp2 inhibition 
(Shp2 inhibition of approximately 20% or above) were moved to the next step of 
analysis. Viable compounds were studied in a dose-dependent manner, testing at three 
concentrations (10 μM, 20 μM, and 30 μM) in triplicate wells, to determine potency. The 
term IC50 was defined as the concentration of an inhibitor at the point of 50% decrease in 
Shp2 activity. For IC50 determination, eight concentrations of known Shp2 inhibitor 
PHPS1 (0.375-50.0 μM) and three concentrations of each test compound (10-30 μM) 
were evaluated in triplicate wells. The curve-fitting program GraphPad Prism 5 (La Jolla, 
CA) was used to calculate IC50 values for PHPS1 and all test compounds. 
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RESULTS 
 
 In conjunction with Dr. John Porco and Dr. Lauren Brown at the Center for 
Molecular Discovery at Boston University, this study aimed to identify, modify, and 
optimize novel Shp2 inhibitors for use as potential treatments for Alzheimer’s disease. Of 
the over 3000 compounds in the library developed at the Center for Molecular Discovery, 
about 1000 have been tested to date. To have a proper understanding of the inhibitive 
properties of the test compounds required the selection of a negative control. Of the three 
compounds previously shown to inhibit Shp2 (refer to Figure 14), PHPS1 demonstrated 
the most promise because of a low Aβ IC50 of 0.09 μM and a maximal inhibition of Aβ40 
of 48%. PHPS1was tested in a dose-dependent manner to assess the potency with regard 
to Shp2 inhibition. Figure 15 shows the dose-response curve generated with eight 
different concentrations of PHPS1 (0.375-50.0 μM).  
 
 
 
 
 
 
 
 
 
Figure 15: Eight-point PHPS1 dose-response curve. 
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The data acquired from the PHPS1 dose-response curve were used to determine the IC50 
of PHPS1 for Shp2. As shown in Figure 16, the IC50 was calculated to be 20.19 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: IC50 determination for PHPS1. 
 
 Test compounds were sent to the lab as 0.2-μmol dry aliquots on 96-well plates. 
After dissolving the compounds in DMSO, a final concentration of 10 μM was used for 
screening purposes. Compounds which tested favorably when compared with the positive 
control, PHPS1, were selected for further study. In addition, these compounds were 
designated for future modifications to create analogs aimed at optimizing Shp2 inhibition. 
To date, dozens of plates have been screened. A few examples are shown in Figures 17-
21, with Table 2 summarizing the compounds which tested favorably.  
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Figure 17: Plate #1652. Analysis of Plate #1652 shows two potential compounds worthy 
of consideration for further study (indicated with red arrows). 
 
Figure 18: Plate #1653. Analysis of Plate #1653 shows one potential compound worthy 
of consideration for further study (indicated with a red arrow). 
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Figure 19: Plate #1654. Analysis of Plate #1654 shows no potential compounds worthy 
of consideration for further study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Plate #1655. Analysis of Plate #1655 shows one potential compound worthy 
of consideration for further study (indicated with a red arrow. 
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Figure 21: Plate #1656. Analysis of Plate #1656 shows one potential compound worthy 
of consideration for further study (indicated with a red arrow). 
 
Table 2 summarizes the five compounds (indicated by red arrows in Figures 17-
21) which tested favorably for Shp2 inhibition when compared with the negative control, 
DMSO, and the positive control, PHPS1. 
Table 2: Summary of test compounds. 
 
Compound (10μM) 
% Inhibition 
(compared with DMSO control) 
PHPS1 24.42 
9491 23.69 
9499 22.79 
9501 20.52 
9506 19.36 
9507 22.34 
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Compounds 9491, 9499, 9501, 9506, and 9507 (Table 2) were tested in a dose-dependent 
manner (10, 20 and 30 μM) to determine their potency with regard to Shp2 inhibition. 
Values of IC50 were calculated, and the results are provided in Figures 22-26. 
 
Figure 22: Three-point dose-response curve for compound #9491. 
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Figure 23: Three-point dose-response curve for compound #9499. 
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Figure 24: Three-point dose-response curve for compound #9501. 
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Figure 25: Three-point dose-response curve for compound #9506. 
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Figure 26: Three-point dose-response curve for compound #9507. 
0
2000
4000
6000
8000
10000
12000
14000
10uM 20uM 30uM
F
lu
o
re
sc
en
ce
 
Concentration (uM) 
Compound #9507 
 39 
 Table 3 summarizes the IC50 determinations for compounds 9491, 9499, 9501, 
9506, and 9507 compared with the positive control, PHPS1. 
Table 3: Summary of IC50 determinations for compounds 9491, 9499, 9501, 9506, 
and 9507. 
 
Compound IC50 (μM) 
PHPS1 20.19 
9491 23.27 
9499 25.76 
9501 24.58 
9506 31.89 
9507 22.63 
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DISCUSSION 
 
 Alzheimer’s disease is a progressive neurodegenerative disorder characterized by 
the accumulation of neurotoxic Aβ peptides and subsequent onset of secondary 
neuropathological changes, including aggregation of hyperphosphorylated tau protein. Aβ 
peptides are produced through the amyloidogenic processing of APP by β- and γ-
secretases. The oligomerization and aggregation of Aβ peptides into neurotoxic amyloid 
plaques serve as a major characteristic hallmark of Alzheimer’s disease in the brain. For 
this reason, the reduction of Aβ formation through inhibition of β- and γ-secretase and 
activation of α-secretase has been a primary focus of many recent therapeutic research 
studies. Other therapeutic strategies include the clearance of Aβ peptides from the 
cerebral cortex through both active and passive immunization. Although current therapies 
have shown some glimpses of promise, they carry a great deal of risk with unintended 
side effects. Moreover, there are currently no disease-modifying drugs available to treat 
Alzheimer’s disease, as most therapeutics are targeted to treat symptoms of the disease 
rather than the disease itself. With a growing aging population and an ever-increasing 
economic burden placed on global healthcare systems, there is a pressing need to develop 
a disease-modifying treatment.  
Ample evidence exists to suggest that the dimerization of APP plays a crucial role 
in Aβ production. To better understand the relationship between APP dimerization and 
Aβ, Pauline So and her colleagues at Boston University performed a high-throughput 
screen to identify APP dimerization inhibitors which reduce Aβ production. APP 
dimerization inhibitor compound Y was found to reduce Aβ production and sAPPβ 
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levels, suggesting that the inhibition of APP dimerization affects β-secretase cleavage of 
APP. A promising structural analog to compound Y, known as Y10, was shown to reduce 
Aβ40 and Aβ42 by more than 50% at 1 μM concentration. The Y series of compounds 
has a heterocyclic core characteristic of several known kinase inhibitors. A kinase 
profiling assay revealed that compound Y10 exhibited its action through the inhibition of 
receptor tyrosine kinase cKit. The single phosphorylated tyrosine residue in APP which 
correlated to Y10-mediated Aβ reduction was later identified as Y687. Known cKit 
interactors with potential to affect downstream APP phosphorylation were studied, 
leading to the discovery of Shp2, a tyrosine phosphatase directly linked to cKit signaling. 
After known Shp2 inhibitors NSC-87877, PHPSI, and II-B08 were demonstrated to 
increase APP phosphorylation and lower Aβ, it was hypothesized that both cKit and Shp2 
are involved in APP processing and Aβ production. The current study aimed to identify 
and optimize small-molecule Shp2 inhibitors for use as a novel therapeutic approach to 
lowering Aβ accumulation in Alzheimer’s disease. 
The difficulty of targeting Shp2 (and phosphatases in general) with inhibitors that 
are sufficiently potent, selective, and permeable for in vivo applications is correlated to 
the phosphatase active-site pocket. This area is generally large and positively charged 
with an ability to bind well to charged phosphomimetics that exhibit low cell 
permeability. The active site of Shp2 is a shallow pocket lined with several cationic 
amino acid side chains involved in phosphotyrosine recognition, including three 
arginines, three lysines, and one histidine. To facilitate binding to Shp2 active sites, 
known Shp2 inhibitors generally feature several anionic groups, high molecular weight, 
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and large total surface area. These features have a potential to be problematic as they are 
highly undesirable in central nervous system (CNS) probes and drugs. 
 A massive compound library of prospective Shp2 inhibitors was assembled in 
collaboration with Dr. John Porco and his colleagues at the Center for Molecular 
Discovery at Boston University with the aforementioned difficulties in mind. Potential 
Shp2 inhibitors were developed to incorporate cation-binding features present in known 
Shp2 inhibitors while also retaining physiochemical properties necessary for future 
applications in CNS drug discovery. These compounds were tested for their ability to 
inhibit Shp2 using DMSO and known Shp2 inhibitor PHPS1 as negative and positive 
controls, respectively. After hundreds of compounds were tested, compounds 9491, 9499, 
9501, 9506, and 9507 showed promise for their ability to inhibit Shp2. These compounds 
were evaluated in a dose-dependent manner to determine their potency with regard to 
Shp2 inhibition. The IC50 determined for compounds 9491, 9499, 9501, 9506, and 9507 
compared favorably with that of known Shp2 inhibitor PHPS1. These lead compounds 
will move to the next stage of testing.  
 Future experiments with these promising compounds will include a secondary 
assay for Shp2 inhibition which uses ERK phosphorylation (pERK) as an indicator of 
Shp2 signaling activity. The compounds will be tested in HEK293 cells stably 
overexpressing APP, and the lysate will be analyzed for the pERK:total ERK ratio using 
specific antibodies. In this study, a reduction in pERK would indicate inhibition of Shp2 
activity. The compounds will then be tested for regulation of APP dimerization and 
phosphorylation in APP stable cell lines and primary neurons. The structure-property 
 43 
relationships driving CNS penetration and the therapeutic potential of the Shp2-targeting 
compounds will be determined by performing blood-brain barrier (BBB) penetration and 
microsomal stability analysis on a subset of compounds. In vitro CNS pharmacokinetic 
studies will be conducted on the final lead candidate. 
 In conclusion, this study was a collaborative effort utilizing medicinal chemistry 
and biochemistry to synthesize, identify, and optimize small-molecule APP dimerization 
inhibitors as a novel therapeutic approach for lowering Aβ production in the treatment of 
Alzheimer’s disease. Ultimately, this work will contribute to the scientific knowledge 
behind Alzheimer’s disease and will provide the necessary tools for the discovery of 
potential therapeutics. 
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